Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma

Authors: Kai Li, Zhong-Zhen Su, Er-Jiao Xu, Jin-Xiu Ju, Xiao-Chun Meng, Rong-Qin Zheng

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

To assess whether intraoperative use of contrast-enhanced ultrasound (CEUS)-CT/MR image fusion can accurately evaluate ablative margin (AM) and guide supplementary ablation to improve AM after hepatocellular carcinoma (HCC) ablation.

Methods

Ninety-eight patients with 126 HCCs designated to undergo thermal ablation treatment were enrolled in this prospective study. CEUS-CT/MR image fusion was performed intraoperatively to evaluate whether 5-mm AM was covered by the ablative area. If possible, supplementary ablation was applied at the site of inadequate AM. The CEUS image quality, the time used for CEUS-CT/MR image fusion and the success rate of image fusion were recorded. Local tumor progression (LTP) was observed during follow-up. Clinical factors including AM were examined to identify risk factors for LTP.

Results

The success rate of image fusion was 96.2 % (126/131), and the duration required for image fusion was 4.9 ± 2.0 (3–13) min. The CEUS image quality was good in 36.1 % (53/147) and medium in 63.9 % (94/147) of the cases. By supplementary ablation, 21.8 % (12/55) of lesions with inadequate AMs became adequate AMs. During follow-up, there were 5 LTPs in lesions with inadequate AMs and 1 LTP in lesions with adequate AMs. Multivariate analysis showed that AM was the only independent risk factor for LTP (hazard ratio, 9.167; 95 % confidence interval, 1.070–78.571; p = 0.043).

Conclusion

CEUS-CT/MR image fusion is feasible for intraoperative use and can serve as an accurate method to evaluate AMs and guide supplementary ablation to lower inadequate AMs.
Literature
1.
go back to reference Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20(3):130–40.CrossRefPubMed Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20(3):130–40.CrossRefPubMed
2.
go back to reference Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78.
3.
go back to reference Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–12. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–12.
4.
go back to reference Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology-Basel. 2007;72 Suppl 1:98–103. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology-Basel. 2007;72 Suppl 1:98–103.
5.
go back to reference Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, Tsuchihashi T, Saigenji K. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188(2):480–8. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, Tsuchihashi T, Saigenji K. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188(2):480–8.
6.
go back to reference Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk f actors and patterns. J Gastroenterol. 2008;43(1):71–8. Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk f actors and patterns. J Gastroenterol. 2008;43(1):71–8.
7.
go back to reference Mori K, Fukuda K, Asaoka H, Ueda T, Kunimatsu A, Okamoto Y, Nasu K, Fukunaga K, Morishita Y, Minami M. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran--feasibility study. Radiology. 2009;251(2):557–65. Mori K, Fukuda K, Asaoka H, Ueda T, Kunimatsu A, Okamoto Y, Nasu K, Fukunaga K, Morishita Y, Minami M. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran--feasibility study. Radiology. 2009;251(2):557–65.
8.
go back to reference Tokunaga S, Koda M, Matono T, Sugihara T, Nagahara T, Ueki M, Murawaki Y, Kakite S, Yamashita E. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT. Br J Radiol. 2012;85(1014):745–52. Tokunaga S, Koda M, Matono T, Sugihara T, Nagahara T, Ueki M, Murawaki Y, Kakite S, Yamashita E. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT. Br J Radiol. 2012;85(1014):745–52.
9.
go back to reference Okubo H, Kokubu S, Komiyama M, Yamagata H, Uchiyama A, Miyazaki A, Watanabe S. Radiofrequency ablation of hepatocellular carcinoma: The feasibility of magnetic resonance imaging with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid for evaluating the ablative margin. Hepatol Res. 2010;40(10):1034–41. Okubo H, Kokubu S, Komiyama M, Yamagata H, Uchiyama A, Miyazaki A, Watanabe S. Radiofrequency ablation of hepatocellular carcinoma: The feasibility of magnetic resonance imaging with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid for evaluating the ablative margin. Hepatol Res. 2010;40(10):1034–41.
10.
go back to reference Makino Y, Imai Y, Igura T, Hori M, Fukuda K, Sawai Y, Kogita S, Ohama H, Matsumoto Y, Nakahara M, Zushi S, Kurokawa M, Isotani K, Takamura M, Fujita N, Murakami T. Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. Hepatol Res. 2013;43(9):950–8. Makino Y, Imai Y, Igura T, Hori M, Fukuda K, Sawai Y, Kogita S, Ohama H, Matsumoto Y, Nakahara M, Zushi S, Kurokawa M, Isotani K, Takamura M, Fujita N, Murakami T. Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. Hepatol Res. 2013;43(9):950–8.
11.
go back to reference Kim Y, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. Am J Roentgenol. 2010;195(3):758–65.CrossRef Kim Y, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. Am J Roentgenol. 2010;195(3):758–65.CrossRef
12.
go back to reference Sakakibara M, Ohkawa K, Katayama K, Imanaka K, Ishihara A, Hasegawa N, Kimura H. Three-dimensional registration of images obtained before and after radiofrequency ablation of hepatocellular carcinoma to assess treatment adequacy. Am J Roentgenol. 2014;202(5):W487–95.CrossRef Sakakibara M, Ohkawa K, Katayama K, Imanaka K, Ishihara A, Hasegawa N, Kimura H. Three-dimensional registration of images obtained before and after radiofrequency ablation of hepatocellular carcinoma to assess treatment adequacy. Am J Roentgenol. 2014;202(5):W487–95.CrossRef
13.
go back to reference Zhong-Zhen S, Kai L, Rong-Qin Z, Er-Jiao X, Ting Z, Ao-Hua Z, Shu-Fang Y, Xu-Qi H. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma. Ultraschall Med. 2012;33(7):E250–5. Zhong-Zhen S, Kai L, Rong-Qin Z, Er-Jiao X, Ting Z, Ao-Hua Z, Shu-Fang Y, Xu-Qi H. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma. Ultraschall Med. 2012;33(7):E250–5.
14.
go back to reference Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34(1):11–29. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34(1):11–29.
15.
go back to reference Dill-Macky MJ, Asch M, Burns P, Wilson S. Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrast-enhanced sonography. AJR Am J Roentgenol. 2006;186(5 Suppl):S287–95.CrossRefPubMed Dill-Macky MJ, Asch M, Burns P, Wilson S. Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrast-enhanced sonography. AJR Am J Roentgenol. 2006;186(5 Suppl):S287–95.CrossRefPubMed
16.
go back to reference Mauri G, Porazzi E, Cova L, Restelli U, Tondolo T, Bonfanti M, Cerri A, Ierace T, Croce D, Solbiati L. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging. 2014;5(2):209–16. Mauri G, Porazzi E, Cova L, Restelli U, Tondolo T, Bonfanti M, Cerri A, Ierace T, Croce D, Solbiati L. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging. 2014;5(2):209–16.
17.
go back to reference Meloni MF, Andreano A, Franza E, Passamonti M, Lazzaroni S. Contrast enhanced ultrasound: Should it play a role in immediate evaluation of liver tumors following thermal ablation? Eur J Radiol. 2012;81(8):e897–902.CrossRefPubMed Meloni MF, Andreano A, Franza E, Passamonti M, Lazzaroni S. Contrast enhanced ultrasound: Should it play a role in immediate evaluation of liver tumors following thermal ablation? Eur J Radiol. 2012;81(8):e897–902.CrossRefPubMed
18.
go back to reference Jung EM, Friedrich C, Hoffstetter P, Dendl LM, Klebl F, Agha A, Wiggermann P, Stroszcynski C, Schreyer AG. Volume navigation with contrast enhanced ultrasound and image fusion for percutaneous interventions: first results. PLoS One. 2012;7(3):e33956. Jung EM, Friedrich C, Hoffstetter P, Dendl LM, Klebl F, Agha A, Wiggermann P, Stroszcynski C, Schreyer AG. Volume navigation with contrast enhanced ultrasound and image fusion for percutaneous interventions: first results. PLoS One. 2012;7(3):e33956.
19.
go back to reference Krucker J, Xu S, Venkatesan A, Locklin JK, Amalou H, Glossop N, Wood BJ. Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol. 2011;22(4):515–24. Krucker J, Xu S, Venkatesan A, Locklin JK, Amalou H, Glossop N, Wood BJ. Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol. 2011;22(4):515–24.
20.
go back to reference Lee MW, Rhim H, Cha DI, Kim YJ, Choi D, Kim YS, Lim HK. Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol. 2012;198(6):1438–44. Lee MW, Rhim H, Cha DI, Kim YJ, Choi D, Kim YS, Lim HK. Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol. 2012;198(6):1438–44.
21.
go back to reference Liu FY, Yu XL, Liang P, Cheng ZG, Han ZY, Dong BW, Zhang XH. Microwave ablation assisted by a real-time virtual navigation system for hepatocellular carcinoma undetectable by conventional ultrasonography. Eur J Radiol. 2012;81(7):1455–9. Liu FY, Yu XL, Liang P, Cheng ZG, Han ZY, Dong BW, Zhang XH. Microwave ablation assisted by a real-time virtual navigation system for hepatocellular carcinoma undetectable by conventional ultrasonography. Eur J Radiol. 2012;81(7):1455–9.
22.
go back to reference Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, Aron M, Gill IS. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012;187(3):1080–6. Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, Aron M, Gill IS. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012;187(3):1080–6.
24.
go back to reference Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95(9):1931–7. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95(9):1931–7.
25.
go back to reference Ikeda K, Seki T, Umehara H, Inokuchi R, Tamai T, Sakaida N, Uemura Y, Kamiyama Y, Okazaki K. Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol. 2007;31(3):485–91. Ikeda K, Seki T, Umehara H, Inokuchi R, Tamai T, Sakaida N, Uemura Y, Kamiyama Y, Okazaki K. Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol. 2007;31(3):485–91.
Metadata
Title
Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma
Authors
Kai Li
Zhong-Zhen Su
Er-Jiao Xu
Jin-Xiu Ju
Xiao-Chun Meng
Rong-Qin Zheng
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2306-1

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine